Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: The PENTA 5 randomised trial

Lancet

Volumn 359, Issue 9308, 2002, Pages 733-740

  Gibb, D M ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CD4 ANTIGEN; LAMIVUDINE; NELFINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CAUSE OF DEATH; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT;

EID: 0037006656     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)07874-1     Document Type: Article

References (28)

1. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals
2. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA Panel
3. Guidelines for the use of antiretroviral agents in pediatric HIV infection
4. Current evidence for the use of paediatric antiretroviral therapy - A PENTA analysis
5. Treatment of human immunodeficiency virus 1-infected children with the protease inhibitor nelfinavir mesylate
6. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children
7. A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection
8. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT Inhibitors
9. Combination of mutations in HIV-1 reverse transcriptase required for resistance to carbocyclic nucleoside 1592U89
10. Design and analysis of randomised clinical trials requiring prolonged observation of each participant, II: Analysis and examples
11. Regression analysis when the dependent variable is truncated normal
12. Age related reference ranges: Significance test for models and confidence intervals for centiles
13. Cross-sectional stature and weight reference curves for the UK 1990
14. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: Week 24 results of a randomized controlled trial- PACTG-377
15. Drug resistance in a trial of nucleoside-analogue and protease inhibitor therapy in children (PENTA 5)
16. A randomized double-blind study of triple nucleoside therapy of abacavir, lamivudine and zidovudine in previously treated human immunodeficiency virus type-1 infected children
17. A randomised double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: The PENTA-4 trial
18. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: Results from a randomized, double-blind trial
19. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type I
20. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults
21. A novel use for abacavir to simplify therapy and reduce long-term toxicity in PI-experienced patients successfully treated with HAART: 48-week results
22. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations
23. Nelfinavir doses should be increased in infants (The PENTA 7 Study)
24. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children
25. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1
26. Kaletra lopinavir /ritonavir in HIV-infected children at 48 weeks
27. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age